ICU Medical (ICUI)

The business has been shaped by major acquisitions that expanded its scale and product reach. The purchase of Hospira Infusion Systems from Pfizer in 2017 strengthened its position in infusion pumps and associated consumables, while the acquisition of Smiths Medical in 2022 added complementary products across infusion, vascular access, and vital care. As a result, ICU Medical operates as one of the more significant dedicated players in the IV therapy market.

Its reporting structure is built around three main areas: consumables, infusion systems, and vital care. Consumables represent the largest share of revenue and include products that are frequently replaced in clinical use. Infusion systems cover electronic pumps and related platforms, while vital care includes products used in monitoring, respiratory support, and other critical care applications.

ICU Medical serves a customer base that includes hospitals, group purchasing organizations, distributors, and healthcare providers. The United States is its largest market, although the company also sells internationally. Its investment case is closely tied to hospital procedure volumes, purchasing cycles for infusion equipment, integration of acquired operations, and the ongoing need for safe and reliable medication delivery across the continuum of care.